Enltisa

Company
R & D
Our focus
News
Development
Contact

News

Home page

News

Press report

Enterprise dynamics

/news_detail/15.html

The first CTA and clinical study of EnliTISA Pharmaceuticals TISA-818 for treating idiopathic pulmonary fibrosis has been approved by the MPA

2023-12-26

On November 27, 2023, EnliTISA Pharmaceuticals TISA-818, a Class I innovative drug for the treatment of idiopathic pulmonary fibrosis, was approved by the MPA.

/news_detail/14.html

Completion of first patient first visit in phase II clinical trial of TISA-818-Inj for the treatment of acute respiratory distress syndrome

2023-11-25

The Phase II clinical trial of TISA-818-Inj for the treatment of acute respiratory distress syndrome (ARDS) recently completed first patient first visit (FPFV), which was led by Professor Zhan Qingyuan of the China-Japan Friendship Hospital and sponsored by EnliTISA (Shang Hai) Pharmaceutical Co., Ltd (Abbreviated as EnliTISA).

/news_detail/13.html

Never forget the original intention and forge ahead with perseverance—— Housewarming of Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (EnliTISA)

2022-11-16

The inauguration ceremony of EnliTISA’s relocation was held on November 10, 2022. Chairman Dr. Gu Ming delivered a grand speech and witnessed this memorable moment together with all staff.

EnliTISA

Tel:+86-021-33758853

Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai

Company
- Company
- Team
- Culture
- Honor
R & D
Our focus
- IPF
- ALI
- RP
- AS
- DFUs
News
- Enterprise dynamics
- Press report
Development
- Recruit
- Staff style
Contact

Copyright ©2022 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO 沪ICP备2022023966号-1 Powered by www.300.cn